CLAIMS

1. ~~A~~ Use of a pharmaceutical combination of ~~at least two types of~~ Trametinib and a kinase ~~inhibitors~~ inhibitor in the manufacture of a medicament for the treatment of pancreatic cancer, wherein the kinase inhibitor is at least one selected from the group consisting of ~~a MEK inhibitor, an FRK inhibitor, a WEE inhibitor, an AURK inhibitor and a ROCK inhibitor for treatment of pancreatic cancer.~~ AD80, Adavosertib, Alisertib, BI-831266 and Y-27632.

~~2. A pharmaceutical combination of a MEK inhibitor and at least one type of kinase inhibitor selected from the group consisting of an FRK inhibitor, a WEE inhibitor, an AURK inhibitor and a ROCK inhibitor for treatment of pancreatic cancer.~~

~~3.~~2. The use of a pharmaceutical combination according to claim 1 ~~or 2~~, wherein the ~~MEK~~ kinase inhibitor is ~~Trametinib.~~ BI-831266.

~~4. The pharmaceutical combination according to any one of claims 1 to 3, wherein~~
~~the FRK inhibitor is AD80,~~
~~the WEE inhibitor is Adavosertib, and~~
~~the AURK inhibitor is Alisertib or BI 831266.~~

~~5.~~3. ~~A~~ Use of a kinase inhibitor ~~for use~~ in combination with ~~a MEK inhibitor~~ Trametinib in the manufacture of a medicament for the treatment of pancreatic cancer, wherein the kinase inhibitor ~~being~~ is at least one selected from the group consisting of ~~an FRK inhibitor, a WEE inhibitor, an AURK inhibitor and a ROCK inhibitor.~~ AD80, Adavosertib, Alisertib, BI-831266 and Y-27632.

~~6.~~4. The use of a kinase inhibitor according to claim ~~5~~ 3, wherein the ~~MEK~~ kinase inhibitor is ~~Trametinib~~ BI-831266.

~~7. The kinase inhibitor according to claim 5 or 6, wherein~~
~~the FRK inhibitor is AD80,~~

~~the WEE inhibitor is Adavosertib, and~~

~~the AURK inhibitor is Alisertib or BI-831266.~~

~~8.~~5. ~~A MEK inhibitor for use~~ Use of Trametinib in combination with ~~at least one type of~~ a kinase inhibitor in the manufacture of a medicament for the treatment of pancreatic cancer, wherein the kinase inhibitor is at least one selected from the group consisting of ~~an FRK inhibitor, a WEE inhibitor, an AURK inhibitor and a ROCK inhibitor, for treatment of pancreatic cancer.~~ AD80, Adavosertib, Alisertib, BI-831266 and Y-27632.

~~9.~~6. The ~~MEK inhibitor~~ use of Trametinib according to claim ~~8~~ 5, wherein the ~~MEK~~ inhibitor is ~~Trametinib.~~ BI-831266.

7. The use of a pharmaceutical combination according to claim 1 or 2, the use of a kinase inhibitor in combination with Trametinib according to claim 3 or 4, or the use of Trametinib in combination with a kinase inhibitor according to claim 5 or 6, wherein the pharmaceutical combination is in a form of formulation containing two or more types of kinase inhibitors together or in a combination of forms of individual formulations of kinase inhibitors.

8. The use of claim 7, wherein the medicament is to be administered together or individually, simultaneously or sequentially to a subject in need of treatment.

~~10. The MEK inhibitor according to claim 8 or 9, wherein~~

~~the FRK inhibitor is AD80,~~

~~the WEE inhibitor is Adavosertib, and~~

~~the AURK inhibitor is Alisertib or BI-831266.~~

~~11. A method for screening an anticancer agent, the method comprising:~~

~~a step of making a test substance be ingested by Drosophila having the following characteristics a) to d):~~

~~a) expression of a mutant Ras85D in which glycine is substituted with aspartic~~

~~acid, valine or cysteine at 12th position of the amino acid sequence of SEQ ID NO: 1,~~

~~b) deletion or suppressed expression of a p53 gene,~~

~~c) overexpression of a Cyclin E gene, and~~

~~d) deletion or suppressed expression of a Med gene;~~

~~a step of measuring survival rate of Drosophila ingesting the test substance; and~~

~~a step of selecting the test substance as a candidate substance for the anticancer agent when the survival rate of Drosophila ingesting the test substance is higher than that of Drosophila not ingesting the test substance.~~

~~12. The method according to claim 11, wherein~~

~~the mutant Ras85D is a protein in which glycine is substituted with aspartic acid at 12th position of the amino acid sequence of SEQ ID NO: 1,~~

~~the p53 gene expression is suppressed by introducing a nucleic acid suppressing the p53 gene expression,~~

~~the Cyclin E is overexpressed by introducing a nucleic acid encoding Cyclin E, and~~

~~the Med gene expression is suppressed by introducing a nucleic acid suppressing the Med gene expression.~~

~~13. The method according to claim 11, wherein the Drosophila is a Drosophila into which a nucleic acid encoding the mutant Ras85D in which glycine is substituted with aspartic acid at 12th position of the amino acid sequence of SEQ ID NO: 1, a p53 gene knockdown nucleic acid, a nucleic acid encoding a Cyclin E gene and a Med gene knockdown nucleic acid are introduced.~~

~~14. A method for screening an anticancer agent, the method comprising:~~

~~a step of rearing, on a food containing a test substance, an egg resulting from mating Drosophila into which a gal4 gene is introduced to Drosophila into which the following nucleic acids a') to d') are introduced:~~

~~a') a nucleic acid having a nucleotide sequence encoding a mutant Ras85D in which glycine is substituted with aspartic acid at 12th position of the amino acid sequence of SEQ ID NO: 1 in a downstream of a UAS sequence,~~

~~b') a nucleic acid having a nucleotide sequence encoding shRNA for a p53 gene in the downstream of a UAS sequence,~~

~~c') a nucleic acid having a nucleotide sequence encoding a Cyclin E gene in the downstream of a UAS sequence, and~~

~~d') a nucleic acid having a nucleotide sequence encoding shRNA for a Med gene in the downstream of a UAS sequence;~~

~~a step of measuring survival rate of Drosophila reared on the food containing the test substance; and~~

~~a step of selecting the test substance as a candidate substance for the anticancer agent when the survival rate of Drosophila reared on the food containing the test substance is higher than that of Drosophila reared on a food not containing the test substance.~~

~~15. The method according to any one of claims 11 to 14, wherein a rearing temperature for Drosophila is adjusted to control the survival rate of Drosophila not ingesting the test substance or Drosophila reared on a food not containing the test substance.~~

~~16. A Drosophila strain having the following characteristics a) to d):~~

~~a) expression of a mutant Ras85D in which glycine is substituted with aspartic acid, valine or cysteine at 12th position of the amino acid sequence of SEQ ID NO: 1,~~

~~b) deletion or suppressed expression of a p53 gene,~~

~~c) overexpression of a Cyclin E gene, and~~

~~d) deletion or suppressed expression of a Med gene.~~

~~17. The Drosophila strain according to claim 16, wherein the strain is introduced with the following nucleic acids a') to d'):~~

~~a') a nucleic acid having a nucleotide sequence encoding a mutant Ras85D in which glycine is substituted with aspartic acid at 12th position of the amino acid sequence of SEQ ID NO: 1 in a downstream of a UAS sequence,~~

~~b') a nucleic acid having a nucleotide sequence encoding shRNA for a p53 gene in the downstream of a UAS sequence,~~

~~c') a nucleic acid having a nucleotide sequence encoding a Cyclin E gene in the downstream of a UAS sequence, and~~

~~d') a nucleic acid having a nucleotide sequence encoding shRNA for a Med gene in the downstream of a UAS sequence.~~